peptide companies tirzepatide GLP1 – Tirz (10-20mg) |

The researchers reported 15 cardiovascular deaths among both groups

[Google Scholar] 3.Achievement of glycaemic targets with weight loss and without hypoglycaemia in type 2 diabetes with the once-weekly glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist tirzepatide: a post hoc analysis of the SURPASS-1 to -5 studies

Certain conditions make semaglutide unsuitable

By targeting both receptors, tirzepatide not only helps improve blood sugar control but also promotes significant weight loss, making it a breakthrough drug for both diabetes and obesity management

It is administered once weekly as a subcutaneous injection